ClearPoint Neuro (CLPT) Projected to Post Quarterly Earnings on Tuesday

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) is expected to be posting its quarterly earnings results after the market closes on Tuesday, March 11th. Analysts expect ClearPoint Neuro to post earnings of ($0.15) per share and revenue of $8.23 million for the quarter. ClearPoint Neuro has set its FY 2025 guidance at EPS.Individual interested in participating in the company's earnings conference call can do so using this link.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.05). ClearPoint Neuro had a negative net margin of 59.64% and a negative return on equity of 62.10%. The business had revenue of $7.77 million during the quarter, compared to the consensus estimate of $8.23 million. On average, analysts expect ClearPoint Neuro to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ClearPoint Neuro Stock Down 0.9 %

Shares of NASDAQ CLPT traded down $0.12 during midday trading on Friday, hitting $13.07. 399,515 shares of the company's stock were exchanged, compared to its average volume of 239,698. ClearPoint Neuro has a 12 month low of $5.11 and a 12 month high of $19.22. The firm has a market capitalization of $361.15 million, a PE ratio of -18.94 and a beta of 1.06. The company's 50 day moving average price is $16.47 and its 200 day moving average price is $13.93.

Remove Ads

Analysts Set New Price Targets

CLPT has been the topic of several research reports. B. Riley upped their target price on ClearPoint Neuro from $15.00 to $20.00 and gave the company a "buy" rating in a research report on Tuesday, January 28th. Lake Street Capital lifted their price objective on shares of ClearPoint Neuro from $17.00 to $30.00 and gave the stock a "buy" rating in a research note on Tuesday, January 21st.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.